Editorial: Androgen-Dependent Diseases And Their Treatment
December 2024
in “
Frontiers in Endocrinology
”
Studysummary This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This editorial discusses the challenges and advancements in treating androgen-dependent diseases such as metastatic castration-resistant prostate cancer (CRPC), benign prostatic hyperplasia (BPH), and polycystic ovary syndrome (PCOS). Despite progress, no treatment is free of side effects. Jian et al. review the molecular mechanisms of CRPC, while Chen et al. analyze the efficacy of treatments like olaparib and abiraterone, finding olaparib monotherapy extends survival. Wang et al. highlight hyperandrogenism's role in PCOS, identifying androstenedione as a diagnostic marker. Alzahrani et al. study BPH prevalence in Saudi Arabia, noting a knowledge gap in risk factors like obesity. The editorial emphasizes the need for continued research and awareness in managing these conditions.
